Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 9,585 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care treatment Clear all
Active, not recruiting Not applicable Interventional

MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence

NCT05735743
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Motivational interviewing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Philadelphia, Pennsylvania • Philadelphia, PA 19123, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Results available

A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

NCT01288989
View directory record Official record
Conditions
Neoplasms
Interventions
IMC-3C5
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Peoria, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 16, 2026, 1:04 AM EDT
Suspended Phase 1Phase 2 Interventional

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589
View directory record Official record
Conditions
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions
Azeliragon, Stereotactic radiosurgery, Corticosteroid
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 16, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional

Sleep-specific DBS Therapy in Parkinson's Disease

NCT05962489
View directory record Official record
Conditions
Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Dystonia
Interventions
Clinically optimized deep brain stimulation
Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Not yet recruiting Phase 2 Interventional

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

NCT07662031
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
Tovecimig, Irinotecan, Leucovorin, 5-Fluorouracil (5-FU)
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT03596645
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab, Infliximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 16, 2026, 1:04 AM EDT
Recruiting Phase 3 Interventional

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

NCT07061977
View directory record Official record
Conditions
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
338
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 261 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)

NCT01521728
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Resistance Exercise, Endurance Exercise, Stretching/Range-of-Motion
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Charlestown, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 16, 2026, 1:04 AM EDT
Not listed Not applicable Interventional

Improving Balance in TBI Using Virtual Reality

NCT02298231
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Standard of Care Balance Intervention, Mystic Isle Balance Intervention, Mystic Isle Balance Intervention with Dual Task
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Implementation of Evidence-Based Practice for Dizziness

NCT05634902
View directory record Official record
Conditions
BPPV, Vestibular Diseases, Vertigo, Dizziness
Interventions
CME Educational Intervention, Study Developed Educational Materials for Patients
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
90,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Terminated Not applicable Interventional

Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors

NCT06654245
View directory record Official record
Conditions
Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Telephone based interview, Survey using a questionnaire., Electronic health record review, Referral
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)

NCT03365895
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer, Neuropathy;Peripheral, Neuropathy
Interventions
Diffusion Tensor Imaging, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 16, 2026, 1:04 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers

NCT02571738
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
CHAM, Control
Biological · Other
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Tucson, Arizona • Carlsbad, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Addressing Low-Income Families' Basic Social Needs at Pediatric Visits

NCT01303458
View directory record Official record
Conditions
Low Income Families Basic Social Needs
Interventions
Basic Needs Surveillance (BNS) protocol
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Boston, Massachusetts • Dorchester, Massachusetts • Roslindale, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment

NCT04788758
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Intervention, Screening Questionnaire Administration, Referral, Questionnaire Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Improving Tobacco Treatment Rates for Cancer Patients Who Smoke

NCT04738643
View directory record Official record
Conditions
Cancer, Tobacco Use, Smoking, Nicotine Dependence
Interventions
Tobacco Use Treatment Service and Varenicline Management
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
Not listed
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

NCT01898208
View directory record Official record
Conditions
Bacteremia, Fungemia, Bloodstream Infection
Interventions
FilmArray testing, Antimicrobial Stewardship, Bacterial culture, Susceptibility testing
Device · Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT03782376
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

NCT03718429
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
Interventions
Rivaroxaban 2.5 mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 16, 2026, 1:04 AM EDT